Early Insomnia Drug Chloral Hydrate Shows Renewed Potential in Severe Cases

Summary: Pharmanovia, in partnership with Lindus Health, announced positive topline results from its open-label RESTORE trial on chloral hydrate for severe insomnia. The trial, which involved 100 adult patients receiving chloral hydrate over 14 days, demonstrated improvements in insomnia severity and quality of life, with benefits persisting for up to four weeks post-treatment. The study…

Read More

Harmony Highlights Orexin-2 Agonist and Pitolisant Advances

Summary: At its Investor Day on October 1, Harmony Biosciences presented a pipeline update, highlighting progress in its sleep disorder treatments. New data from the orexin-2 agonist BP1.15205 showed potential best-in-class potency, while long-term extension data for pitolisant in idiopathic hypersomnia demonstrated sustained efficacy, improving patients’ Epworth Sleepiness Scale scores by approximately 9 points. Notably,…

Read More